HRMY

$0.00

(

+0.00%

)
Quote details

stock

Harmony Biosciences Holdings

NASDAQ | HRMY

36.87

USD

+0.00

(

+0.00%

)

AT CLOSE (AS OF Aug 15, 2025)

$2.1B

MARKET CAP

11.78

P/E Ratio

3.1

EPS

$42

52 Week High

$26

52 Week Low

LIFE SCIENCES

Sector

HRMY Chart

Recent Chart
Price Action
1D
Candles

Trade Smarter

Automate your trading workflow with powerful tools — built for serious traders.

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback's Trading Journal

HRMY Technicals

Tags:

HRMY Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $558M
Total Revenue $715M
Cost Of Revenue $157M
Costof Goods And Services Sold $157M
Operating Income $191M
Selling General And Administrative $110M
Research And Development $146M
Operating Expenses $367M
Investment Income Net -
Net Interest Income $1M
Interest Income $19M
Interest Expense $17M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $24M
Income Before Tax $192M
Income Tax Expense $46M
Interest And Debt Expense -
Net Income From Continuing Operations $145M
Comprehensive Income Net Of Tax -
Ebit $209M
Ebitda $233M
Net Income $145M

Revenue & Profitability

Earnings Performance

HRMY Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $999M
Total Current Assets $579M
Cash And Cash Equivalents At Carrying Value $453M
Cash And Short Term Investments $453M
Inventory $7.2M
Current Net Receivables $83M
Total Non Current Assets $420M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $113M
Intangible Assets Excluding Goodwill $113M
Goodwill -
Investments -
Long Term Investments $109M
Short Term Investments $14M
Other Current Assets $22M
Other Non Current Assets -
Total Liabilities $340M
Total Current Liabilities $175M
Current Accounts Payable $14M
Deferred Revenue -
Current Debt -
Short Term Debt $16M
Total Non Current Liabilities $165M
Capital Lease Obligations -
Long Term Debt $163M
Current Long Term Debt $16M
Long Term Debt Noncurrent -
Short Long Term Debt Total $179M
Other Current Liabilities $145M
Other Non Current Liabilities $1.9M
Total Shareholder Equity $659M
Treasury Stock -
Retained Earnings $2.2M
Common Stock $1K
Common Stock Shares Outstanding $58M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow $220M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $24M
Capital Expenditures $1.2M
Change In Receivables -
Change In Inventory -$1.8M
Profit Loss -
Cashflow From Investment -$67M
Cashflow From Financing -$11M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $0
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $145M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $558M
Total Revenue $715M
Cost Of Revenue $157M
Costof Goods And Services Sold $157M
Operating Income $191M
Selling General And Administrative $110M
Research And Development $146M
Operating Expenses $367M
Investment Income Net -
Net Interest Income $1M
Interest Income $19M
Interest Expense $17M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $24M
Income Before Tax $192M
Income Tax Expense $46M
Interest And Debt Expense -
Net Income From Continuing Operations $145M
Comprehensive Income Net Of Tax -
Ebit $209M
Ebitda $233M
Net Income $145M

HRMY News

HRMY Profile

Harmony Biosciences Holdings Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.

Discover more tools and features to empower your trading
Explore Features

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.